collection
https://read.qxmd.com/read/38491815/reduced-dose-chemotherapy-followed-by-blinatumomab-in-induction-therapy-for-newly-diagnosed-b-cell-acute-lymphoblastic-leukemia
#1
JOURNAL ARTICLE
Jing Lu, Huifen Zhou, Xin Zhou, Yonggong Yang, Laigen Tong, Miao Miao, Xiaofei Yang, Suning Chen
BACKGROUND: Blinatumomab early-line treatment in B-cell precursor acute lymphoblastic leukemia (B-ALL) might improve clinical outcomes. METHODS: We conducted a retrospective real-world cohort analysis in 20 newly diagnosed B-ALL patients who received reduced-dose chemotherapy (idarubicin, vindesine, and dexamethasone) for 1-3 weeks, followed by blinatumomab for 1-4 weeks as an induction therapy. RESULTS: At the end of the induction therapy, a complete remission rate of 100% was achieved; 17 (85%) patients were minimal residual disease (MRD) negative (<1 × 10-4 )...
March 2024: Cancer Medicine
https://read.qxmd.com/read/28809129/effect-of-methotrexate-vitamin-b-12-on-dna-methylation-as-a-potential-factor-in-leukemia-treatment-related-neurotoxicity
#2
JOURNAL ARTICLE
Victoria J Forster, Alex McDonnell, Rachel Theobald, Jill A McKay
UNLABELLED: Methotrexate (MTX) is administered to treat childhood acute lymphoblastic leukemia (ALL). It acts by inhibiting dihydrofolate reductase which reduces methyltetrahydrofolate, a key component in one carbon metabolism, thus reducing cell proliferation. Further perturbations to one carbon metabolism, such as reduced vitamin B12 levels via the use of nitrous oxide for sedation during childhood ALL treatment, may increase neurotoxicity risk. With B12 as an enzymatic cofactor, methyltetrahydrofolate is essential to produce methionine, which is critical for DNA methylation...
September 2017: Epigenomics
https://read.qxmd.com/read/38484899/effect-of-non-pharmacological-interventions-on-symptoms-and-quality-of-life-in-patients-with-hematological-malignancies-a-systematic-review
#3
REVIEW
Maja Pedersen, Mette Schaufuss Engedal, Anders Tolver, Maria Torp Larsen, Brian Thomas Kornblit, Kirsten Lomborg, Mary Jarden
BACKGROUND: Non-pharmacological interventions have the potential to enhance health-related quality of life (HRQoL) through symptom management. This systematic review aims to identify, collate, and assess randomized controlled trials investigating the effect of non-pharmacological interventions on symptoms and HRQoL within hematology. METHODS: MEDLINE/PUBMED, EMBASE, CINAHL, PSYCINFO and COCHRANE were searched up to April 2021. Outcomes were changes in symptoms and HRQoL...
March 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38476120/efficacy-of-definitive-radiotherapy-for-patients-with-clinical-stage-iiib-or-iiic-lung-adenocarcinoma-and-epidermal-growth-factor-receptor-egfr-mutations-treated-using-first-or-second-generation-egfr-tyrosine-kinase-inhibitors
#4
JOURNAL ARTICLE
Chih-Yen Tu, Te-Chun Hsia, Ying-Chun Lin, Ji-An Liang, Chia-Chin Li, Chun-Ru Chien
BACKGROUND: The effectiveness of definitive radiotherapy (RT) for patients with clinical stage IIIB or IIIC lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations who received first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) is unclear. METHODS: Taiwan Cancer Registry data were used in this retrospective cohort study to identify adult patients diagnosed with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma between 2011 and 2020...
2024: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
https://read.qxmd.com/read/37334316/effect-of-radiotherapy-dose-on-outcome-in-nonmetastatic-ewing-sarcoma
#5
JOURNAL ARTICLE
Josephine Kersting, Andreas Ranft, Vivek Bhadri, Bénédicte Brichard, Stéphane Collaud, Sona Cyprová, Hans Eich, Torben Ek, Hans Gelderblom, Jendrik Hardes, Lianne Haveman, Wolfgang Hartmann, Peter Hauser, Philip Heesen, Heribert Jürgens, Jukka Kanerva, Thomas Kühne, Anna Raciborska, Jelena Rascon, Victor Rechl, Arne Streitbürger, Beate Timmermann, Yasmine Uhlenbruch, Uta Dirksen
PURPOSE: Radiation therapy (RT) is an integral part of Ewing sarcoma (EwS) therapy. The Ewing 2008 protocol recommended RT doses ranging from 45 to 54 Gy. However, some patients received other doses of RT. We analyzed the effect of different RT doses on event-free survival (EFS) and overall survival (OS) in patients with EwS. METHODS AND MATERIALS: The Ewing 2008 database included 528 RT-admitted patients with nonmetastatic EwS. Recommended multimodal therapy consisted of multiagent chemotherapy and local treatment consisting of surgery (S&RT group) and/or RT (RT group)...
2023: Advances in Radiation Oncology
https://read.qxmd.com/read/38450850/chronic-myelomonocytic-leukemia-2024-update-on-diagnosis-risk-stratification-and-management
#6
JOURNAL ARTICLE
Mrinal M Patnaik, Ayalew Tefferi
DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%-20% over 3-5 years). DIAGNOSIS: Newly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 109 /L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, <20% BM or PB blasts (including promonocytes), and cytogenetic or molecular evidence of clonality...
March 7, 2024: American Journal of Hematology
https://read.qxmd.com/read/38450790/2024-update-on-allogeneic-hematopoietic-stem-cell-transplant-for-myelofibrosis-a-review-of-current-data-and-applications-on-risk-stratification-and-management
#7
JOURNAL ARTICLE
Haris Ali, Andrea Bacigalupo
BACKGROUND: Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed. AIMS: The aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF patients undergoing an allogeneic HSCT. METHODS: Published papers were used to analyze different aspects of allogeneic HSCT...
March 7, 2024: American Journal of Hematology
https://read.qxmd.com/read/33923121/diagnosis-and-management-of-rectal-neuroendocrine-tumors-nets
#8
REVIEW
Francesco Maione, Alessia Chini, Marco Milone, Nicola Gennarelli, Michele Manigrasso, Rosa Maione, Gianluca Cassese, Gianluca Pagano, Francesca Paola Tropeano, Gaetano Luglio, Giovanni Domenico De Palma
Rectal neuroendocrine tumors (NETs) are rare, with an incidence of 0.17%, but they represent 12% to 27% of all NETs and 20% of gastrointestinal NETs. Although rectal NETs are uncommon tumors, their incidence has increased over the past few years, and this is probably due to the improvement in detection rates made by advanced endoscopic procedures. The biological behavior of rectal NETs may be different: factors predicting the risk of metastases have been identified, such as size and grade of differentiation...
April 25, 2021: Diagnostics
https://read.qxmd.com/read/38429858/smouldering-multiple-myeloma-to-seek-or-not-to-seek-to-treat-or-not-to-treat-that-is-the-question
#9
JOURNAL ARTICLE
Iuliana Vaxman, Moshe E Gatt
In this issue, the British Society for Haematology presents guidelines for the diagnosis and management of patients with smouldering multiple myeloma (SMM). The authors provide a practical, evidence-based approach to managing these patients. Key questions remain yet unsolved. Commentary on: Hughes et al. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19333.
March 1, 2024: British Journal of Haematology
https://read.qxmd.com/read/38450447/neurocognitive-correlates-of-metabolic-dysregulation-in-individuals-with-mood-disorders-a-systematic-review-and-meta-analysis
#10
REVIEW
Kateryna Maksyutynska, Nicolette Stogios, Femin Prasad, Jashan Gill, Zaineb Hamza, Riddhita De, Emily Smith, Angelina Horta, Benjamin I Goldstein, Daphne Korczak, Ariel Graff-Guerrero, Margaret K Hahn, Sri Mahavir Agarwal
Individuals with mood disorders are predisposed to metabolic dysfunction, while those with metabolic dysregulation such as diabetes and obesity experience more severe depressive symptoms. Both metabolic dysfunction and mood disorders are independently associated with cognitive deficits. Therefore, given their close association, this study aimed to explore the association between metabolic dysfunction in individuals with mood disorders in relation to cognitive outcomes. A comprehensive search comprised of these three domains was carried out; a random-effects meta-analysis pooling mean cognitive outcomes was conducted (PROSPERO ID: CRD42022295765)...
March 7, 2024: Psychological Medicine
https://read.qxmd.com/read/38396839/current-understanding-of-immune-thrombocytopenia-a-review-of-pathogenesis-and-treatment-options
#11
REVIEW
Alina Mititelu, Minodora-Cezarina Onisâi, Adrian Roșca, Ana Maria Vlădăreanu
The management of immune thrombocytopenia (ITP) and the prediction of patient response to therapy still represent a significant and constant challenge in hematology. ITP is a heterogeneous disease with an unpredictable evolution. Although the pathogenesis of ITP is currently better known and its etiology has been extensively studied, up to 75% of adult patients with ITP may develop chronicity, which represents a significant burden on patients' quality of life. A major risk of ITP is bleeding, but knowledge on the exact relationship between the degree of thrombocytopenia and bleeding symptoms, especially at a lower platelet count, is lacking...
February 10, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/37195076/american-society-of-hematology-2023-guidelines-for-management-of-venous-thromboembolism-thrombophilia-testing
#12
JOURNAL ARTICLE
Saskia Middeldorp, Robby Nieuwlaat, Lisa Baumann Kreuziger, Michiel Coppens, Damon Houghton, Andra H James, Eddy Lang, Stephan Moll, Tarra Myers, Meha Bhatt, Chatree Chai-Adisaksopha, Luis E Colunga-Lozano, Samer G Karam, Yuan Zhang, Wojtek Wiercioch, Holger J Schünemann, Alfonso Iorio
Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables...
November 28, 2023: Blood Advances
https://read.qxmd.com/read/38378673/update-on-the-management-of-relapsed-refractory-chronic-lymphocytic-leukemia
#13
REVIEW
Rory Bennett, John F Seymour
Chronic lymphocytic leukemia (CLL) predominantly affects older adults, characterized by a relapsing and remitting pattern with sequential treatments available for many patients. Identification of progressive/relapsed CLL should prompt close monitoring and early discussion about the next therapies when treatment indications are present. The intervening period represents an opportunity to optimize patient health, including establishing adequate vaccination and surveillance for second primary malignancies, and treating non-CLL-related comorbidities which may impact well-being and CLL therapy...
February 21, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38375926/venetoclax-in-the-treatment-of-acute-myeloid-leukemia-beyond-viale-a
#14
JOURNAL ARTICLE
Naseema Gangat, Ayalew Tefferi
Venetoclax and hypomethylating agent therapy in acute myeloid leukemia.
February 20, 2024: American Journal of Hematology
https://read.qxmd.com/read/38436779/clinical-outcomes-of-patients-with-cic-rearranged-sarcoma-a-single-institution-retrospective-analysis
#15
JOURNAL ARTICLE
Jacob Murphy, Erin E Resch, Christopher Leland, Christian F Meyer, Nicolas J Llosa, John M Gross, Christine A Pratilas
PURPOSE: CIC-rearranged sarcomas represent a type of undifferentiated small round cell sarcoma (USRCS) characterized by poor survival, rapid development of chemotherapy resistance, and high rates of metastasis. We aim to contribute to the growing body of knowledge regarding diagnosis, treatment, clinical course, and outcomes for these patients. METHODS: This case series investigates the clinical courses of ten patients with CIC-rearranged sarcoma treated at the Johns Hopkins Hospital from July 2014 through January 2024...
March 4, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38249542/update-on-therapeutic-approaches-for-invasive-fungal-infections-in-adults
#16
REVIEW
Catherine-Audrey Boutin, Me-Linh Luong
Invasive fungal infections are increasingly encountered with the expansion of iatrogenic immunosuppression, including not only solid organ and hematopoietic stem cell transplant recipients but also patients with malignancies or autoimmune diseases receiving immunomodulatory therapies, such as Bruton Tyrosine Kinase (BTK) inhibitor. Their attributable mortality remains elevated, part of which is a contribution from globally emerging resistance in both molds and yeasts. Because antifungal susceptibility test results are often unavailable or delayed, empiric and tailored antifungal approaches including choice of agent(s) and use of combination therapy are heterogeneous and often based on clinician experience with knowledge of host's net state of immunosuppression, prior antifungal exposure, antifungal side effects and interaction profile, clinical severity of disease including site(s) of infection and local resistance data...
2024: Therapeutic Advances in Infectious Disease
https://read.qxmd.com/read/37735554/novel-therapeutics-and-future-directions-for-refractory-immune-thrombocytopenia
#17
REVIEW
Hanny Al-Samkari, Ellis J Neufeld
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting approximately 1 in 20 000 people. While most patients with ITP are successfully managed with the current set of standard and approved therapeutics, patients who cannot be adequately managed with these therapies, considered to have refractory ITP, are not uncommon. Therefore, there remains an ongoing need for novel therapeutics and drug development in ITP. Several agents exploiting novel targets and mechanisms in ITP are presently under clinical development, with trials primarily recruiting heavily pretreated patients and those with otherwise refractory disease...
October 2023: British Journal of Haematology
https://read.qxmd.com/read/38361116/autologous-stem-cell-boost-improves-persistent-immune-effector-cell-associated-hematotoxicity-following-bcma-directed-chimeric-antigen-receptor-t-car-t-cell-therapy-in-multiple-myeloma
#18
JOURNAL ARTICLE
Meera Mohan, Aniko Szabo, Anannya Patwari, Jean Esselmann, Tanvi Patel, Ramya Bachu, Lisa E Rein, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Catherine Skoog, Areyl Goff, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Sharmilan Thanendrarajan, Maurizio Zangari, Nirav Shah, Frits van Rhee, Binod Dhakal, Mehdi Hamadani, Anita D'Souza, Carolina Schinke
Persistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed multiple myeloma (MM). The use of stem cell boosts in ICAHT has been described, however studies have been limited by small patient numbers and short follow up. Herein, we report on our multi-institutional experience of ICAHT, defined by an absolute neutrophil count (ANC) of ≤ 1000, thrombocytopenia with a platelet count ≤ 50,000 or/and anemia as hemoglobin (hgb) ≤9 g/dL, in patients who received BCMA CAR T therapy, and the effects of subsequent stem cell boost on hematopoietic reconstitution and clinical outcome...
February 15, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38375783/the-mozart-effect-in-chronic-myeloid-leukaemia
#19
JOURNAL ARTICLE
Jesper Stentoft
Clinical research has not been able to establish whether the differences between first- and second-generation BCR-ABL 1 kinase inhibitors are clinically relevant with regard to outcome. In the study by Alcazer et al., a relevant difference seems to emerge-paradoxically in the absence of the drugs-as demonstrated by differences in the relapse kinetics after cessation of therapy. Commentary on: Alcazer et al. Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients...
February 20, 2024: British Journal of Haematology
https://read.qxmd.com/read/38429997/dietary-interventions-in-cancer-a-systematic-review-of-all-randomized-controlled-trials
#20
JOURNAL ARTICLE
Nosakhare Paul Ilerhunmwuwa, Abul Hasan Shadali Abdul Khader, Calvin Smith, Edward R Scheffer Cliff, Christopher M Booth, Evevanne Hottel Rd, Muhammad Aziz, Wade Lee-Smith, Aaron Goodman, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin
BACKGROUND: Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic review, we assessed all RCTs investigating dietary interventions for cancer patients, examining the range of interventions, endpoints, patient populations, and results. METHODS: This systematic review identified all RCTs conducted prior to January 2023 testing dietary interventions in patients with cancer. Assessed outcomes included quality of life, functional outcomes, clinical cancer measurements (eg, progression-free survival, response rates), overall survival, and translational endpoints (eg, inflammatory markers)...
March 1, 2024: Journal of the National Cancer Institute
label_collection
label_collection
1090
1
2
2024-03-05 00:25:32
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.